Paxalisib breast cancer trial triples size at Kazia (NASDAQ: KZIA)
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Kazia Therapeutics is expanding its ongoing Phase 1b trial of lead drug paxalisib in advanced triple negative breast cancer. Planned enrollment will rise from 12 to 36 patients after continued encouraging safety, tolerability and early clinical activity in combination with pembrolizumab and chemotherapy.
The larger study is intended to refine dosing and better assess early measures of benefit such as objective response rate, progression-free survival and translational biomarkers. Kazia highlights preclinical data supporting dual PI3K/mTOR inhibition in TNBC and notes that additional clinical updates are anticipated throughout 2026 and into 2027.
Positive
- None.
Negative
- None.
Insights
Trial expansion reflects encouraging early signals but remains an early-stage, high‑risk program.
Kazia is tripling enrollment in its Phase 1b paxalisib trial in advanced triple negative breast cancer from 12 to 36 patients. This move typically indicates acceptable safety and enough preliminary activity to justify a larger dataset, still within an exploratory setting.
The study focuses on paxalisib plus pembrolizumab and chemotherapy, with objectives including safety, dose optimization, objective response rate and progression-free survival. Results will be based on a small, open-label cohort, so outcomes may not predict later-stage trials. Subsequent disclosures across 2026–2027 will clarify whether the signal remains strong.
Key Figures
Planned enrollment (before): 12 patients
Planned enrollment (after expansion): 36 patients
TNBC share of breast cancer: 15 to 20 percent
+5 more
8 metrics
Planned enrollment (before)
12 patients
Initial Phase 1b paxalisib TNBC trial enrollment
Planned enrollment (after expansion)
36 patients
Expanded Phase 1b paxalisib TNBC trial enrollment
TNBC share of breast cancer
15 to 20 percent
Proportion of all breast cancer diagnoses attributed to TNBC
Paxalisib clinical trials
10 clinical trials
Number of clinical studies paxalisib is or has been part of
GBM-Agile report year
2024
Phase 2/3 glioblastoma study completion and reporting year
Glioblastoma Orphan designation year
February 2018
FDA Orphan Drug Designation for paxalisib in glioblastoma
Glioblastoma Fast Track year
August 2020
FDA Fast Track Designation for paxalisib in glioblastoma
Brain metastases Fast Track year
July 2023
FDA Fast Track Designation for paxalisib in solid tumor brain metastases
Key Terms
Phase 1b, triple negative breast cancer, objective response rate, Orphan Drug Designation, +2 more
6 terms
Phase 1b financial
"plans to expand its ongoing Phase 1b clinical trial evaluating lead asset paxalisib"
"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.
triple negative breast cancer medical
"patients with advanced triple negative breast cancer (“TNBC”)"
Triple negative breast cancer is a type of breast cancer that lacks three common markers used to identify and target the disease, making it more challenging to treat. It tends to grow and spread more quickly than other forms, which can lead to more aggressive outcomes. Its complexity can impact medical research and treatment developments, influencing investor interest in healthcare companies working on new therapies.
objective response rate medical
"provide a more meaningful assessment of objective response rate (“ORR”), progression-free survival"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
Orphan Drug Designation regulatory
"Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Fast Track Designation (FTD) for glioblastoma in August 2020"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
Rare Pediatric Disease Designation regulatory
"Paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA"
A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.
FAQ
What did Kazia Therapeutics (KZIA) announce in this Form 6-K?
Kazia Therapeutics announced plans to expand its ongoing Phase 1b trial of paxalisib in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients to gain a more robust view of safety, dosing, and early efficacy signals in combination therapy.
How is Kazia Therapeutics changing the paxalisib breast cancer trial design?
The company is increasing planned enrollment in its Phase 1b paxalisib trial from 12 to 36 patients with advanced triple negative breast cancer. The expansion aims to better evaluate safety, tolerability, dose optimization, objective response rate, progression-free survival and translational biomarker readouts.
Why did Kazia Therapeutics withdraw its ASCO 2026 abstracts?
Kazia states it withdrew planned ASCO 2026 abstracts solely to protect its intellectual property position ahead of anticipated filings. The company emphasizes that the withdrawal was not driven by safety or clinical concerns and still plans to share further clinical and translational data updates.
What cancer type is targeted by Kazia’s expanded paxalisib trial?
The expanded Phase 1b trial targets advanced triple negative breast cancer, a subtype accounting for about 15–20 percent of breast cancer diagnoses and associated with poorer outcomes. Paxalisib is being tested with pembrolizumab and chemotherapy to address resistance and immune-related pathways in this population.
What other indications is Kazia testing paxalisib in besides breast cancer?
Beyond advanced breast cancer, paxalisib is or has been studied in glioblastoma, brain metastases, diffuse midline gliomas and primary central nervous system lymphoma. Several of these trials have reported encouraging interim data, and a Phase 2/3 glioblastoma study (GBM-Agile) was completed and reported in 2024.
What regulatory designations has paxalisib received from the FDA?
Paxalisib has multiple U.S. FDA designations, including Orphan Drug and Fast Track for glioblastoma, Fast Track for solid tumor brain metastases with PI3K pathway mutations, and Rare Pediatric Disease and Orphan designations for diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumors.